메뉴 건너뛰기




Volumn 30, Issue 4, 2014, Pages 613-627

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: A systematic review and mixed treatment comparison

Author keywords

Efficacy; Mixed treatment comparison; Multiple sclerosis; Relapsing; Remitting; RRMS; Safety

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; BETA INTERFERON; CROTONIC ACID DERIVATIVE; FUMARIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TOLUIDINE DERIVATIVE;

EID: 84896456479     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.863755     Document Type: Review
Times cited : (65)

References (45)
  • 1
    • 54149084585 scopus 로고    scopus 로고
    • Multiple sclerosis
    • Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
    • (2008) Lancet , vol.372 , pp. 1502-1517
    • Compston, A.1    Coles, A.2
  • 2
    • 84867916552 scopus 로고    scopus 로고
    • Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach
    • Gasperini C, Ruggieri S. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther 2012;6:175-86
    • (2012) Drug des Devel Ther , vol.6 , pp. 175-186
    • Gasperini, C.1    Ruggieri, S.2
  • 3
    • 84874074752 scopus 로고    scopus 로고
    • Onset of secondary progressive phase and long-term evolution of multiple sclerosis
    • Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;70:214-22
    • (2013) J Neurol Neurosurg Psychiatry , vol.70 , pp. 214-222
    • Scalfari, A.1    Neuhaus, A.2    Daumer, M.3
  • 4
    • 84896464812 scopus 로고    scopus 로고
    • National Multiple Sclerosis Society. The MS Disease - Modifying Medications. 2013. Available at [Last accessed 8 August 2011]
    • National Multiple Sclerosis Society. The MS Disease - Modifying Medications. 2013. Available at: www.nationalmssociety.org [Last accessed 8 August 2011]
  • 5
    • 84896461578 scopus 로고    scopus 로고
    • Electronic Medicines Compendium. Electronic Medicines Compendium. Available at [Last accessed August 2011]
    • Electronic Medicines Compendium. Electronic Medicines Compendium. Available at: http://emc.medicines.org.uk/ [Last accessed August 2011]
  • 6
    • 84866355653 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
    • Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
    • (2012) N Engl J Med , vol.367 , pp. 1087-1097
    • Fox, R.J.1    Miller, D.H.2    Phillips, J.T.3
  • 7
    • 69149107165 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    • W64
    • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64
    • (2009) Ann Intern Med , vol.151 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 8
    • 0029914622 scopus 로고    scopus 로고
    • Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
    • (1996) Control Clin Trials , vol.17 , pp. 1-12
    • Jadad, A.R.1    Moore, R.A.2    Carroll, D.3
  • 9
    • 84896458149 scopus 로고    scopus 로고
    • NICE STA. Specification for manufacturer/sponsor submission of evidence October 2009. Available at [Last accessed August 2011]
    • NICE STA. Specification for manufacturer/sponsor submission of evidence October 2009. Available at: http://www.nice.org.uk/aboutnice/howwework/ devnicetech/singletechnologyappraisalsubmissiontemplates.jsp?domedia= 1&mid=4D9D8C83-19B9-E0B5-D4B0E148B3FE727F [Last accessed August 2011]
  • 10
    • 84896445080 scopus 로고    scopus 로고
    • IQWiG. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: General methods. Available at [Last accessed September 2011]
    • IQWiG. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: General methods. Available at: https://www.iqwig.de/download/ IQWiG- General-methods-V-3-0.pdf [Last accessed September 2011]
  • 11
    • 84896449642 scopus 로고    scopus 로고
    • The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions. Available at [Last accessed April 2013]
    • The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions. Available at: http://handbook.cochrane.org/ [Last accessed April 2013]
  • 12
    • 0348012903 scopus 로고    scopus 로고
    • A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients
    • Milanese C, La ML, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-92
    • (2003) J Neurol Neurosurg Psychiatry , vol.74 , pp. 1689-1692
    • Milanese, C.1    La, M.L.2    Palumbo, R.3
  • 13
    • 80053302178 scopus 로고    scopus 로고
    • The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: Are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination
    • Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord 2011;4:281-96
    • (2011) Ther Adv Neurol Disord , vol.4 , pp. 281-296
    • Limmroth, V.1    Putzki, N.2    Kachuck, N.J.3
  • 14
    • 33846118263 scopus 로고    scopus 로고
    • Rates and probabilities in economic modelling: Transformation, translation and appropriate application
    • Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6
    • (2007) Pharmacoeconomics , vol.25 , pp. 3-6
    • Fleurence, R.L.1    Hollenbeak, C.S.2
  • 15
    • 84866423965 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
    • Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
    • (2012) N Engl J Med , vol.367 , pp. 1098-1107
    • Gold, R.1    Kappos, L.2    Arnold, D.L.3
  • 16
    • 17644436776 scopus 로고
    • Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
    • Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-40
    • (1993) J Interferon Res , vol.13 , pp. 333-340
    • Knobler, R.L.1    Greenstein, J.I.2    Johnson, K.P.3
  • 17
    • 69949098534 scopus 로고    scopus 로고
    • 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study
    • O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
    • (2009) Lancet Neurol , vol.8 , pp. 889-897
    • O'connor, P.1    Filippi, M.2    Arnason, B.3
  • 18
    • 19644372979 scopus 로고    scopus 로고
    • Effects of dose titration on tolerability and efficacy of interferon beta- 1b in people with multiple sclerosis
    • Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta- 1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
    • (2005) J Int Med Res , vol.33 , pp. 309-318
    • Wroe, S.J.1
  • 19
    • 0029161628 scopus 로고
    • Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
    • Sibley WA, Duquette P, Knobler RL, et al. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
    • (1995) Neurology , vol.45 , pp. 1277-1285
    • Sibley, W.A.1    Duquette, P.2    Knobler, R.L.3
  • 20
    • 80054944461 scopus 로고    scopus 로고
    • Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    • Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;18:418-424
    • (2011) Multiple Sclerosis , vol.18 , pp. 418-424
    • Calabrese, M.1    Bernardi, V.2    Atzori, M.3
  • 21
    • 33645470729 scopus 로고    scopus 로고
    • Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis
    • Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
    • (2006) Acta Neurol Scand , vol.113 , pp. 283-287
    • Etemadifar, M.1    Janghorbani, M.2    Shaygannejad, V.3
  • 22
    • 0023248694 scopus 로고
    • A pilot trial of cop 1 in exacerbating- remitting multiple sclerosis
    • Bornstein MB, Miller A, Slagle S. A pilot trial of cop 1 in exacerbating- remitting multiple sclerosis. N Engl J Med 1987;317:408-14
    • (1987) N Engl J Med , vol.317 , pp. 408-414
    • Bornstein, M.B.1    Miller, A.2    Slagle, S.3
  • 23
    • 78650159514 scopus 로고    scopus 로고
    • Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Results of a phase II randomised placebo-controlled multicentre trial
    • Kappos L, Calabresi P, Connor P, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis 2010; 16:S33-4
    • (2010) Multiple Sclerosis , vol.16
    • Kappos, L.1    Calabresi, P.2    Connor, P.3
  • 24
    • 67649476210 scopus 로고    scopus 로고
    • Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study
    • Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
    • (2009) Neurology , vol.72 , pp. 1976-1983
    • Cadavid, D.1    Wolansky, L.J.2    Skurnick, J.3
  • 25
    • 84880843972 scopus 로고    scopus 로고
    • Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing remitting multiple sclerosis
    • 10-13 October 2012. Lyon, France, P491
    • Calabresi PA, Goodin D, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing remitting multiple sclerosis. 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 10-13 October 2012. Lyon, France, P491
    • 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)
    • Calabresi, P.A.1    Goodin, D.2    Jeffery, D.3
  • 26
    • 33644584352 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    • Polman CH, Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910
    • (2006) N Engl J Med , vol.354 , pp. 899-910
    • Polman, C.H.1    Connor, P.W.2    Havrdova, E.3
  • 27
    • 76149093586 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    • Kappos L, Radue EW, Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362: 387-401
    • (2010) N Engl J Med , vol.362 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    Connor, P.3
  • 28
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
    • (2010) N Engl J Med , vol.362 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3
  • 29
    • 80053533877 scopus 로고    scopus 로고
    • Randomized trial of oral teriflunomide for relapsing multiple sclerosis
    • O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365: 1293-303
    • (2011) N Engl J Med , vol.365 , pp. 1293-1303
    • O'connor, P.1    Wolinsky, J.S.2    Confavreux, C.3
  • 31
    • 77955044842 scopus 로고    scopus 로고
    • Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis
    • De Stefano N, Curtin F, Stubinski B, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2010;16:888-92
    • (2010) Multiple Sclerosis , vol.16 , pp. 888-892
    • De Stefano, N.1    Curtin, F.2    Stubinski, B.3
  • 33
    • 84875657789 scopus 로고    scopus 로고
    • Recent advances in treating multiple sclerosis: Efficacy, risks and place in therapy
    • Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis 2013;4:45-51
    • (2013) Ther Adv Chronic Dis , vol.4 , pp. 45-51
    • Jeffery, D.R.1
  • 34
    • 84896455775 scopus 로고    scopus 로고
    • Safety profile of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: Long-term interim results from the ENDORSE extension study
    • 2-5 October 2013. Copenhagen, Denmark
    • Phillips JT, Fox RJ, Selmaj K, et al. Safety profile of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2-5 October 2013. Copenhagen, Denmark
    • 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • Phillips, J.T.1    Fox, R.J.2    Selmaj, K.3
  • 35
    • 82455215753 scopus 로고    scopus 로고
    • Heterogeneity in multiple sclerosis: Scratching the surface of a complex disease
    • Disanto G, Berlanga AJ, Handel AE, et al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis 2010; 2011:932351
    • (2010) Autoimmune Dis , vol.2011 , pp. 932351
    • Disanto, G.1    Berlanga, A.J.2    Handel, A.E.3
  • 37
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebocontrolled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis
    • Ebers GC, Rice G, Lesaux J, et al. Randomised double-blind placebocontrolled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
    • (1998) Lancet , vol.352 , pp. 1498-1504
    • Ebers, G.C.1    Rice, G.2    Lesaux, J.3
  • 38
    • 36849035929 scopus 로고    scopus 로고
    • Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon (beta)-1a for relapsing multiple sclerosis
    • Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon (beta)-1a for relapsing multiple sclerosis. Clin Therapeut 2007;29:2031-48
    • (2007) Clin Therapeut , vol.29 , pp. 2031-2048
    • Schwid, S.R.1    Panitch, H.S.2
  • 39
    • 51449101000 scopus 로고    scopus 로고
    • Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
    • Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
    • (2008) Lancet Neurol , vol.7 , pp. 903-914
    • Mikol, D.D.1    Barkhof, F.2    Chang, P.3
  • 40
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double- blind, placebo-controlled trial
    • Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 1995;45:1268-76
    • (1995) Neurology , vol.45 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 41
    • 0035091667 scopus 로고    scopus 로고
    • European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
    • Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7
    • (2001) Ann Neurol , vol.49 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 42
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
    • Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-94
    • (1996) Ann Neurol , vol.39 , pp. 285-294
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3
  • 43
    • 0037181634 scopus 로고    scopus 로고
    • Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
    • Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359: 1453-60
    • (2002) Lancet , vol.359 , pp. 1453-1460
    • Durelli, L.1    Verdun, E.2    Barbero, P.3
  • 44
    • 84866021501 scopus 로고    scopus 로고
    • A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
    • Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis 2012;18:1269-77
    • (2012) Multiple Sclerosis , vol.18 , pp. 1269-1277
    • Saida, T.1    Kikuchi, S.2    Itoyama, Y.3
  • 45
    • 33645799680 scopus 로고    scopus 로고
    • A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    • O'Connor P, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
    • (2006) Neurology , vol.66 , pp. 894-900
    • O'connor, P.1    Li, D.2    Freedman, M.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.